Business Wire

Veristat Announces Global Cell and Gene Therapy Center of Excellence

Share

Cell and gene therapies represent the next great wave of therapeutic innovation and have led to the development of promising therapies worldwide.

Veristat, a scientific minded clinical research organization, announced today the launch of their Global Cell and Gene Therapy Center of Excellence (COE). The COE comprises a multi-disciplinary team of scientific experts who are adept at strategy and execution across this complex clinical development pathway. Veristat’s experience supporting these unique programs in the Americas and Europe enables them to implement impactful advisory and tactical services to support the challenging decisions required to advance a cell and gene therapy to market. Leveraging the learnings from the support of numerous client cell and gene therapy programs, including the first gene therapy approved in Europe, the Global COE will serve as a powerhouse for sponsors and as a mechanism to share insights, successful strategies, and best practices.

“We understand how high the stakes are with cell and gene therapy programs,” stated Alecia Barbee, Executive Vice President, Operations at Veristat, “and that nothing is standard about the therapies, the studies or the regulatory processes in this specialized area. Veristat has successfully supported more than 100 cell and gene therapy projects across the entire clinical development life-cycle, and with the launch of our center of excellence, we are formalizing our processes to assist sponsors around the globe to bring these advanced therapies to market quickly.”

Every cell or gene therapy is unique, often coming with a complicated regulatory approval process and unique therapeutic challenges. Even the best therapeutic may not reach patients who need it if the study design and execution are not optimal. Veristat offers tailored solutions across the entire clinical development pathway to combat these challenges, including:

  • The ability to develop your therapeutic with accelerated approval pathways and/or special designations
  • A review of operational aspects of the protocol and feedback on any potential obstacles/challenges that could impact the protocol execution at the clinical research sites
  • Novel strategies including implementation of a centralized site model and remote monitoring with direct-to-patient capabilities
  • Expertise in logistics and handling of live cellular material
  • Development of bespoke regulatory strategies for the type of cell and gene therapy and the unmet clinical need acceptable to the regulatory agencies
  • Long-term follow-up strategies to meet global regulatory requirements

“The challenges of developing cell and gene therapies requires a committed and experienced partner,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “Cell and gene therapies offer uniquely curative potential for disorders that are intractable to other treatment modalities. They can save lives. The challenge now is to scale the opportunity they offer to their full potential. Our years of experience in this specialized area and reputation for success will make Veristat the CRO of choice for small and medium biopharmaceutical companies who want to bring their cell or gene therapies to patients worldwide.”

About Veristat:

Veristat, a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years' experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared nearly 100 marketing applications for approval with global regulatory authorities in the last ten years.

Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. For more information, visit www.veristat.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Veristat Contact:
Lauren Willis, Marketing Manager
marketing@veristat.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Strike Launches Bitcoin App in Europe24.4.2024 16:00:00 CEST | Press release

Strike, the global bitcoin app, today announced the launch of its platform to eligible customers in Europe. Strike Europe introduces a comprehensive suite of features designed to empower millions of people with access to Bitcoin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424407807/en/ Strike Europe App (Photo: Business Wire) Customers can sign up in a few clicks, seamlessly and securely buy bitcoin with free, instant, and unlimited deposits, and sell, send, and withdraw just as easily. The platform also facilitates global payments and offers advanced Bitcoin and Lightning wallet services. Strike is available for download on iOS and Android app stores. Key features of Strike Europe include: Buy bitcoin directly with free unlimited SEPA Euro deposits from your bank account Sell bitcoin and withdraw the funds directly to your SEPA bank account Withdraw bitcoin to self-custody or send it to any Bitcoin or Lightning walle

Parker Aerospace Joins HyFIVE Consortium to Advance Aviation Liquid Hydrogen Fuel System Development24.4.2024 16:00:00 CEST | Press release

Parker Aerospace, a business segment of Parker Hannifin Corporation, the global leader in motion and control technologies, will participate in the HyFIVE consortium of industry and academic partners developing a world-leading liquid hydrogen fuel system and supply chain supporting zero-emission aviation in the 2030s. In addition to Parker Aerospace, HyFIVE includes fellow industry partners Marshall and GKN Aerospace, as well as academic partners University of Manchester, University of Bath and Cardiff University. The project is supported by the ATI Programme, a partnership between the UK’s Department for Business and Trade, the Aerospace Technology Institute (ATI) and Innovate UK (UKRI). The consortium will receive initial funding of £17 million ($21.5 million) from industry, matched by £20 million ($25 million) from the UK Government. A path to zero emissions flight The objective of the HyFIVE consortium is to develop, test and validate a modular and scalable cryogenic hydrogen fuel s

Ouro and Real Madrid Partner to Deliver Innovative Financial Products to Football Fans Around the Globe24.4.2024 15:53:00 CEST | Press release

Ouro, a global financial services and technology innovator, and the Real Madrid Football Club today announced a strategic partnership agreement to develop and deliver co-branded financial solutions to fans in key markets globally, including the United States, Mexico, Brazil, Portugal, France and the United Arab Emirates. The alliance makes Ouro the exclusive partner of the men's and women's football teams for the prepaid, debit and credit card product categories. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424106690/en/ The signing event held April 15 in Madrid with Ouro founders Bertrand Sosa and Roy Sosa and Emilio Butragueño, Real Madrid’s Director of Institutional Relations. (Photo: Business Wire) From the April 15 signing event in Madrid, Emilio Butragueño, Real Madrid’s Director of Institutional Relations, commented, “It’s hugely gratifying. They are leaders in financial services who will partner with us in count

EBP Shareholders Enter into Exclusive Negotiations with Cegid to Create a European Leader in the Highly Strategic and Growing Market for Micro and SMB Enterprise Software24.4.2024 15:36:00 CEST | Press release

Cegid, a European leader in cloud business management solutions for finance (treasury, tax, ERP), human resources (payroll, talent management), CPAs, retail and entrepreneurial sectors, strengthens its position in the fast-growing sector of invoicing and accounting software solutions for the Micro and SMB segments through the potential acquisition of EBP, one of the leading enterprise software providers in this market segment. Following Cegid’s investments in Iberia and Belgium, this major step will allow the new Cegid Group to become the leader in this high-growth market segment ahead of the implementation of mandatory e-invoicing. EBP, established as one of the leading solutions providers in France known for its long-standing expertise in working with Micro and SMB businesses, its user-centered approach and its distinctive know-how, has been serving its customer base of 275,000 companies using its solutions in France for close to 40 years. The acquisition of EBP represents a major st

Exergen Sues Baxter International to Defend Its Right to Publish Data Regarding the Accuracy of Oral Thermometers24.4.2024 15:00:00 CEST | Press release

Last week Exergen Corporation filed a lawsuit against Baxter International Inc. in the United States District Court for the District of Massachusetts. As detailed in its complaint, Exergen’s lawsuit is a response to an effort by Baxter to censor true statements that Exergen has made in a scientific journal about a matter of public concern, among other issues. Through its lawsuit, Exergen seeks a legal declaration that its statements are not only true, but that they constitute First Amendment protected speech. Exergen looks forward to having this matter resolved in a court of law. Click here to read the formal complaint. About Exergen Corporation Exergen invented, manufactures, and markets two series of the TemporalScanner thermometer: a professional version for hospitals and clinics, and a consumer version sold in major retailers nationwide. More than three billion temperatures are taken each year with TemporalScanners. Used in thousands of hospitals and clinics across the country as w

HiddenA line styled icon from Orion Icon Library.Eye